Literature DB >> 9804855

Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest.

C D Scatena1, Z A Stewart, D Mays, L J Tang, C J Keefer, S D Leach, J A Pietenpol.   

Abstract

There is increasing evidence that prolonged mitotic arrest initiates apoptosis; however, little is known about the signaling pathways involved. Several studies have associated deregulated Cdc2 activity with apoptosis. Herein, we report that the anti-apoptotic protein, Bcl-2, undergoes cell cycle-dependent phosphorylation during mitosis when there is elevated Cdc2 activity. We found that paclitaxel (Taxol(R)) treatment of epithelial tumor cells induced a prolonged mitotic arrest, elevated levels of mitotic kinase activity, hyperphosphorylation of Bcl-2, and subsequent cell death. The Taxol-induced Bcl-2 phosphorylation was dose-dependent. Furthermore, phosphorylated Bcl-2 remained complexed with Bax in Taxol-treated cells undergoing apoptosis. Immunoprecipitation experiments revealed a Bcl-2-associated kinase capable of phosphorylating histone H1 in vitro. However, the kinase was likely not cyclin B1/Cdc2, since cyclin B1/Cdc2 was not detectable in Bcl-2 immunoprecipitates, nor was recombinant Bcl-2 phosphorylated in vitro by cyclin B1/Cdc2. The results of this study further define a link between mitotic kinase activation and the apoptotic machinery in the cell. However, the role, if any, of prolonged Bcl-2 phosphorylation in Taxol-mediated apoptosis awaits further definition of Bcl-2 mechanism of action. Taxol may increase cellular susceptibility to apoptosis by amplifying the normal downstream events associated with mitotic kinase activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9804855     DOI: 10.1074/jbc.273.46.30777

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  53 in total

Review 1.  Cell cycle checkpoints as therapeutic targets.

Authors:  Z A Stewart; J A Pietenpol
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-10       Impact factor: 2.673

Review 2.  Cell cycle and apoptosis.

Authors:  Katrien Vermeulen; Zwi N Berneman; Dirk R Van Bockstaele
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

3.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

4.  Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1.

Authors:  N Pathan; C Aime-Sempe; S Kitada; S Haldar; J C Reed
Journal:  Neoplasia       Date:  2001 Jan-Feb       Impact factor: 5.715

Review 5.  Clusterin and chemoresistance.

Authors:  Julie Y Djeu; Sheng Wei
Journal:  Adv Cancer Res       Date:  2009       Impact factor: 6.242

Review 6.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

7.  Targeting PLK1 overcomes T-DM1 resistance via CDK1-dependent phosphorylation and inactivation of Bcl-2/xL in HER2-positive breast cancer.

Authors:  Özge Saatci; Simone Borgoni; Özge Akbulut; Selvi Durmuş; Umar Raza; Erol Eyüpoğlu; Can Alkan; Aytekin Akyol; Özgür Kütük; Stefan Wiemann; Özgür Şahin
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867

8.  Contribution of Bcl-2 phosphorylation to Bak binding and drug resistance.

Authors:  Haiming Dai; Husheng Ding; X Wei Meng; Sun-Hee Lee; Paula A Schneider; Scott H Kaufmann
Journal:  Cancer Res       Date:  2013-10-04       Impact factor: 12.701

9.  Growth-inhibiting effects of intralesional docetaxel and paclitaxel on an experimental model of malignant neuroectodermal tumor.

Authors:  C Morales; M Zurita; J Vaquero
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

10.  A phase I pharmacokinetic and pharmacodynamic correlative study of the antisense Bcl-2 oligonucleotide g3139, in combination with carboplatin and paclitaxel, in patients with advanced solid tumors.

Authors:  Glenn Liu; Jill Kolesar; Douglas G McNeel; Catherine Leith; Kathy Schell; Jens Eickhoff; Fred Lee; Anne Traynor; Rebecca Marnocha; Dona Alberti; James Zwiebel; George Wilding
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.